Kazia Therapeutics LTD (KZIA) — SEC Filings

Overview

Kazia Therapeutics LTD (KZIA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B3 filed on Apr 15, 2026: Kazia Therapeutics Ltd. filed a prospectus supplement on April 15, 2026, related to its common stock. The filing details the terms of a proposed offering, though specific dollar amounts and the number of shares are not immediately clear from this document alone. This is a routine filing to update th

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 1 bearish, 49 neutral. The dominant filing sentiment for Kazia Therapeutics LTD is neutral.

Filing Type Overview

Kazia Therapeutics LTD (KZIA) has filed 4 424B3, 40 6-K, 2 20-F, 2 SC 13G/A, 2 SC 13G with the SEC between Mar 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• 424B3 Filing — 424B3 · Apr 15, 2026
• Kazia Therapeutics Files Prospectus Supplement — 424B3 · Apr 15, 2026 Risk: medium
  Kazia Therapeutics Ltd. filed a prospectus supplement on April 15, 2026, related to its common stock. The filing details the terms of a proposed offering, thoug
• Kazia Therapeutics Files Prospectus Supplement — 424B3 · Apr 15, 2026 Risk: medium
  Kazia Therapeutics Ltd. filed a prospectus supplement on April 15, 2026, related to its common stock. The filing details the terms of a public offering, though
• Kazia Therapeutics Files Prospectus Supplement — 424B3 · Apr 15, 2026 Risk: medium
  Kazia Therapeutics Ltd. filed a prospectus supplement (424B3) on April 15, 2026, related to its securities. The filing originates from Sydney, Australia, with t
• 6-K Filing — 6-K · Mar 30, 2026
• Kazia Therapeutics Files 6-K on Staff Determination Letter — 6-K · Dec 19, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on December 19, 2025, reporting on a staff determination letter received on November 12, 2025. The filing is for the
• Kazia Therapeutics Presents Paxalisib Data — 6-K · Dec 10, 2025 Risk: medium
  On December 10, 2025, Kazia Therapeutics Limited issued a press release highlighting new clinical and translational findings for its drug candidate, paxalisib.
• 6-K Filing — 6-K · Dec 5, 2025
• 6-K Filing — 6-K · Dec 2, 2025
• 6-K Filing — 6-K · Nov 18, 2025
• Kazia's Losses Mount to A$134.8M Amidst Plummeting Licensing Revenue — 20-F · Nov 7, 2025 Risk: high
  KAZIA THERAPEUTICS LTD reported significant net losses for the fiscal year ended June 30, 2025, totaling A$20.7 million, following losses of A$26.8 million in 2
• Kazia Therapeutics Files October 2025 6-K Report — 6-K · Oct 7, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 7, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer
• Kazia Therapeutics Files 6-K Report — 6-K · Oct 2, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on October 2, 2025. The company, based in Sydney, NSW, Australia, is a foreign private issuer
• Kazia Therapeutics Files September 2025 6-K Report — 6-K · Sep 11, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on September 11, 2025, reporting for the month of September 2025. The company, previously known as Novogen Ltd, is i
• Kazia Therapeutics Announces Private Placement — 6-K · Aug 1, 2025 Risk: medium
  On July 31, 2025, Kazia Therapeutics Limited entered into a securities purchase agreement with certain institutional and accredited purchasers for a private pla
• Kazia Therapeutics Files Form 6-K — 6-K · Jul 25, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on July 25, 2025, reporting information for the month of July 2025. The company, previously known as Novogen Ltd, is
• Kazia Therapeutics Files Form 6-K — 6-K · Jul 9, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on July 9, 2025. The company, based in Sydney, NSW, is a foreign private issuer and is submit
• Kazia Therapeutics Files Form 6-K — 6-K · Jun 11, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 11, 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations
• Kazia Therapeutics Files 6-K with Financial Updates — 6-K · Jun 10, 2025 Risk: low
  Kazia Therapeutics Ltd. filed a 6-K report on June 10, 2025, detailing financial information for the period ending December 31, 2024. The report includes financ
• Kazia Therapeutics Files Form 6-K — 6-K · Jun 5, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 5, 2025. The company, headquartered in Sydney, NSW, is reporting for the month of Jun
• Kazia Therapeutics Files May 2025 6-K Report — 6-K · May 28, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on May 28, 2025, reporting its activities for the month of May 2025. The company, previously known as Novogen Ltd, i
• Kazia Therapeutics Files 6-K, Formerly Novogen Ltd — 6-K · May 15, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on May 15, 2025, reporting information as a foreign private issuer. The filing details the company's principal execu
• Kazia Therapeutics to change ADS to Ordinary Share ratio — 6-K · Apr 15, 2025 Risk: low
  Kazia Therapeutics Limited announced on April 15, 2025, a planned change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio wil
• Kazia Therapeutics Files March 2025 6-K Report — 6-K · Mar 31, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on March 31, 2025, reporting for the month of March 2025. The company, headquartered in Sydne
• Kazia Therapeutics Files 2024 Annual Report — 6-K · Mar 13, 2025 Risk: low
  Kazia Therapeutics Limited filed its Annual Report to shareholders for the fiscal year ended June 30, 2024, on March 11, 2025. The report is attached as Exhibit
• Kazia Therapeutics Files 6-K Report — 6-K · Feb 20, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on February 20, 2025. The company, based in Sydney, NSW, operates in the pharmaceutical prepa
• Kazia Therapeutics Files 6-K Report — 6-K · Feb 3, 2025 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on February 3, 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparati
• Kazia Therapeutics Files January 2025 6-K Report — 6-K · Jan 30, 2025 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on January 30, 2025, reporting for the month of January 2025. The company, previously known as Novogen Ltd, is based
• Kazia Therapeutics Announces Registered Direct Offering — 6-K · Jan 13, 2025 Risk: medium
  On January 10, 2025, Kazia Therapeutics Limited entered into a securities purchase agreement with an institutional investor for a registered direct offering and
• Kazia Therapeutics Files 6-K Report — 6-K · Dec 31, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on December 31, 2024, reporting for the month of December 2024. The company, based in Sydney,
• Kazia Therapeutics Files 6-K Report — 6-K · Dec 11, 2024 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on December 11, 2024. The filing is a report of a foreign private issuer and indicates that Kazia Therapeutics Limit
• Kazia Therapeutics Files 20-F for FY24 — 20-F · Nov 15, 2024 Risk: medium
  Kazia Therapeutics Ltd. filed its annual 20-F report for the fiscal year ending June 30, 2024. The company, formerly Novogen Ltd., is based in Sydney, NSW, Aust
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Kazia Therapeutics Files Routine 6-K Report — 6-K · Nov 12, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on November 12, 2024. The filing is a report of a foreign private issuer and does not specify
• SC 13G Filing — SC 13G · Nov 6, 2024
• Kazia Therapeutics Files Routine 6-K — 6-K · Nov 4, 2024 Risk: low
  Kazia Therapeutics Limited, based in Sydney, NSW, filed a Form 6-K on November 4, 2024. This report is for the month of November 2024 and indicates the company
• Kazia Therapeutics Changes ADS to Ordinary Share Ratio — 6-K · Oct 15, 2024 Risk: low
  Kazia Therapeutics Limited announced on October 15, 2024, a change in the ratio of its American Depositary Shares (ADSs) to Ordinary Shares. The ratio will chan
• Kazia Therapeutics Files 6-K Report — 6-K · Oct 2, 2024 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on October 2, 2024. The filing is a report of a foreign private issuer and indicates that the company files annual r
• Kazia Therapeutics Files 6-K with SEC — 6-K · Sep 23, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 23, 2024. The company, headquartered in Sydney, NSW, is a foreign private issuer
• Kazia Therapeutics Files Form 6-K — 6-K · Sep 13, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on September 13, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical prepara
• SC 13G/A Filing — SC 13G/A · Aug 12, 2024
• Kazia Therapeutics Files Routine 6-K Report — 6-K · Jul 10, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on July 10, 2024. The company, based in Sydney, NSW, Australia, is a foreign private issuer a
• SC 13G Filing — SC 13G · Jul 2, 2024
• Kazia Therapeutics Files June 2024 6-K Report — 6-K · Jun 24, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on June 24, 2024. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations
• Kazia Therapeutics Faces Nasdaq Listing Deficiency — 6-K · May 23, 2024 Risk: medium
  Kazia Therapeutics Limited received a deficiency notification from Nasdaq on November 20, 2023, regarding its non-compliance with listing requirements. The comp
• Kazia Therapeutics Reports on Warrant Issuance — 6-K · May 17, 2024 Risk: low
  On December 5, 2023, Kazia Therapeutics Limited issued an "Existing Warrant" allowing the purchase of up to 4,444,445 American Depositary Shares (ADSs). Each AD
• Kazia Therapeutics Files 6-K Report — 6-K · May 1, 2024 Risk: low
  Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on May 1, 2024. The company, based in Sydney, NSW, is a pharmaceutical preparations company a
• Kazia Therapeutics Secures $10M Stock Purchase Agreement — 6-K · Apr 19, 2024 Risk: medium
  On April 19, 2024, Kazia Therapeutics Limited entered into a purchase agreement with Alumni Capital LP, allowing the company to sell up to $10 million of its co
• Kazia Therapeutics Files 6-K for Q2 2023 — 6-K · Mar 27, 2024 Risk: medium
  Kazia Therapeutics Ltd. filed a Form 6-K for the period ending December 31, 2023. The company, formerly Novogen Ltd., is based in Sydney, NSW, Australia. This f
• Kazia Therapeutics Files 6-K Report — 6-K · Mar 26, 2024 Risk: low
  Kazia Therapeutics Limited filed a Form 6-K on March 26, 2024, reporting for the month of March 2024. The company, formerly known as Novogen Ltd, is based in Sy

Risk Profile

Risk Assessment: Of KZIA's 41 recent filings, 1 were flagged as high-risk, 10 as medium-risk, and 30 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• John Friend, M.D.

Industry Context

The biotechnology sector, particularly companies focused on oncology therapeutics like Kazia, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Success is often binary, depending on clinical trial outcomes and market adoption. The competitive landscape is intense, with numerous companies vying for breakthroughs in treating complex diseases.

Top Tags

foreign-private-issuer (19) · regulatory-filing (13) · sec-filing (10) · reporting (7) · pharmaceuticals (5) · 6-K (5) · prospectus-supplement (3) · filing (3) · compliance (3) · securities (3)

Key Numbers

• Form Type: 424B3 — Indicates a prospectus supplement filing
• File Number: 333-292303 — Associated with the registration statement for the offering
• CIK Number: 0001075880 — Unique identifier for Kazia Therapeutics Ltd.
• Net Loss: A$20.7M — For fiscal year 2025, indicating continued unprofitability.
• Accumulated Losses: A$134.8M — As of June 30, 2025, highlighting significant historical unprofitability.
• Revenue: A$42K — For fiscal year 2025, a drastic 98% decrease from A$2.3M in 2024, showing declining licensing income.
• Funds Raised: A$16M — From ADS sales in 2025, indicating reliance on equity financing.
• Ordinary Shares Outstanding: 809,418,734 — As of June 30, 2025, a large share count for a company with minimal revenue.
• ADS Ratio: 1:500 — Effective April 17, 2025, indicating significant reverse splits to manage ADS price.
• Reporting Period End Date: 2024-12-31 — The report covers financial data up to this date.
• Comparative Period End Date: 2023-12-31 — Financial data from this prior period is included for comparison.
• Old ADS to Ordinary Share Ratio: 1:100 — Current ratio before the change
• New ADS to Ordinary Share Ratio: 1:500 — New ratio after the change
• SEC File Number: 000-29962 — Identifies the specific filing with the SEC
• Fiscal Year End: 2024-06-30 — Reporting period for the 20-F filing.

Related Companies

KZA

Frequently Asked Questions